Increased cancer risk after liver transplantation: a population-based study

Increased cancer risk after liver transplantation: a population-based study
复制标题

DOI:
10.1016/s0168-8278(00)00077-5
复制
发表时间:
2001-01-01
影响因子:
25.7
通讯作者:
Jansen, PLM
Jansen, PLM
中科院分区:
医学1区
文献类型:
--
作者:
Haagsma, EB;Hagens, VE;Jansen, PLM

文献摘要

被引文献

相似文献

背景/目标:原发性恶性肿瘤的发生是肝移植术后的一个严重的长期并发症。方法:我们回顾了174例原发性恶性肿瘤存活一年的成年患者的病历,将观察到的癌症发生率与荷兰人群的预期癌症发生率进行比较。皮肤癌和唇癌占23种恶性肿瘤中的12种(52%)。只有一名患者患有B细胞淋巴瘤。移植后5年、10年和15年新发恶性肿瘤的累积风险分别为6%、20%和55%,与一般人群相比的总体相对风险(RR)为4.3(95%置信区间2.4-7.1),观察到非黑色素瘤皮肤癌的RR显著增加(RR 70.0),非皮肤实体癌(RR 2.7),肾细胞癌(RR 30.0)和结肠癌多因素分析显示,年龄> 40岁和移植前免疫抑制剂的使用是重要的危险因素。肝移植后患癌症的风险增加,包括皮肤癌/唇癌和其他实体瘤。年龄较大和使用免疫抑制剂是危险因素。(C)2001年欧洲肝脏研究协会。由Elsevier Science B. V.出版,版权所有。
Background/Aims: Development of de novo malignancies emerges as a serious long term complication after liver transplantation.Methods: We reviewed the medical records of 174 adult one-year survivors for de novo malignancies, The observed cancer rates were compared with the expected cancer rates in the Dutch population.Results: Twenty-one of the 174 patients developed 23 malignancies (12%). Skin and lip cancer accounted for 12 of the 23 malignancies (52%). Only one patient had a B-cell lymphoma. The cumulative risk for de novo malignancy was 6, 20, and 55% at 5, 10, and 15 years after transplantation, respectively, The overall relative risk (RR) as compared with the general population was 4.3 (95% confidence interval 2.4-7.1), Significantly increased RRs were observed for nonmelanoma skin cancer (RR 70.0), non-skin solid cancer (RR 2.7), renal cell cancer (RR 30.0), and colon cancer (RR 12.5), Multivariate analysis showed that an age > 40 years and pretransplant use of immunosoppression were significant risk factors.Conclusions: An increased risk of cancer exists after liver transplantation, for both for skin/lip cancer, and other solid tumors. Older age and the use of immunosuppression are risk factors.(C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.